Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
Novo Nordisk announced that its Phase 3 STEP Young trial met its primary endpoint, demonstrating that once-weekly semaglutide injections reduced obesity rates and lowered BMI in children aged 6 to under 12. Data shows 40.4% of children in the trial saw a positive response. The results target a demographic with limited existing weight loss therapeutic options. Despite the clinical success, Novo Nordisk shares fell nearly 2% following the announcement, which coincided with the cancellation of two other trials.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The Phase 3 STEP Young trial evaluating once-weekly semaglutide in children aged 6 to under 12 met its primary endpoint.
- ✓ Data from the STEP Young trial indicates 40.4% of children responded to the treatment.
- ✓ The drug showed effectiveness in reducing obesity rates and BMI among children.
What changed
Novo Nordisk released topline Phase 3 STEP Young data showing semaglutide effectiveness in children aged 6 to 12.
Live updates
-
Novo Nordisk Wegovy Trial Reduces Obesity in Children Aged 6 to 12
Novo Nordisk announced that its Phase 3 STEP Young trial met its primary endpoint, demonstrating that once-weekly semaglutide injections reduced obesity rates and lowered BMI in children aged 6 to under 12. Data shows 40.4% of children in the trial saw a positive response. The results target a demographic with limited existing weight loss therapeutic options. Despite the clinical success, Novo Nordisk shares fell nearly 2% following the announcement, which coincided with the cancellation of two other trials.
Why it matters
Wegovy is an injectable weight-loss drug based on semaglutide. Expanding its use to younger children addresses a gap in pediatric obesity treatment. The company's stock performance reflects a balance between this clinical win and other trial setbacks.
What is confirmed
- The Phase 3 STEP Young trial evaluating once-weekly semaglutide in children aged 6 to under 12 met its primary endpoint.
- Data from the STEP Young trial indicates 40.4% of children responded to the treatment.
- The drug showed effectiveness in reducing obesity rates and BMI among children.
Still unconfirmed
- Novo Nordisk shares dropped nearly 2% due to the combination of the childhood trial result and two other trial cancellations.
- Barclays lowered its target price for Novo Nordisk to 300 Danish kroner.
What to watch next
- Regulatory filing and approval decisions for semaglutide use in children aged 6 to 12
- Further details on the two cancelled trials mentioned in financial reports
confidence 90%Sources used for this update (10)
- WSJ — Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
- reuters.com — Novo Nordisk says semaglutide cut obesity rates in young children in trial
- globenewswire.com — Novo Nordisk STEP Young phase 3 data: 40.4% of children
- ynetnews.com — Weight-loss drug shows promise in children as young as 6 in early trial
- Yahoo Finance — Novo is Down Nearly 2% as a 40.4% Childhood Win Meets Two Trial Cancellations
- www.marketscreener.com — Barclays cuts target price for Novo Nordisk to 300 Danish kroner (310), reiterates equal weight - BN
- finance.yahoo.com — Novo Nordisk Phase 3 Trial Meets Primary Endpoint for Child Obesity Drug
- www.yahoo.com — Novo’s Wegovy touts obesity-treating potential in patients as young as six
- www.yahoo.com — Wegovy for Overweight Young Children: Novo Nordisk’s Obesity Drug Shows Effectiveness
- www.healio.com — Injectable Wegovy lowers BMI among children with obesity
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community